| INTRODUC TI ON
Human T-lymphotropic virus (HTLV) was first isolated among the human retroviruses in the early 1980s. 1 It is estimated that [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] million people are infected with HTLV type I/II around the world. [2] [3] [4] HTLV-I/II infection has been known to be transmitted vertically between mother and child, sexually, or by blood transfusion or needles. 5 In cases with blood-borne infection which is strictly related to contaminated lymphocytes, seroconversion occurs in approximately 40% ~ 60% of the recipients in approximately 51 days. 6 Although adult T-cell leukemia (ATL) and HTLV-I-associated myelopathy/tropical spastic paraparesis(HAM/TSP) occur in less than 10% of HTLV-I carriers infected by contaminated bloods, they are generally serious and often cause the patients disabled. 
| MATERIAL S AND ME THODS

| Specimens
This study was conducted at the Department of Laboratory The samples were excluded if there were precipitates or turbidity, or the volume was less than 1 mL.
| Anti-HTLV-I/II assays and confirmatory tests
Elecsys HTLV-I/II assay detects anti-HTLV-I/II against the HTLVspecific recombinant antigens HTLV-I gp21 and HTLV-II p24. The test was run on Cobas 8000 modular analyzer (Roche), a fully automated electrochemiluminescence immunoassay (ECLIA) analyzer.
ARCHITECT rHTLV-I/II assay (Abbott Laboratories) was a comparator assay, which used synthetic peptides and recombinant antigens derived from gp46 and gp21 proteins of HTLV-I/II to capture antibodies. This test was run on ARCHITECT i2000 immunoassay analyzer (Abbott Laboratories), a fully automated CMIA analyzer. All samples were simultaneously tested with the two assays according to the manufacturers' recommendations. For the specimens with discrepant or positive results by either one of the two, both assays were repeated. Only for the discrepant samples, a confirmatory test using MP Diagnostics HTLV Blot 2.4. (MP Biomedicals) was applied.
| Data analysis
Clinical 
| RE SULTS
A total of 102 anti-HTLV-positive samples were tested simultane- The clinical specificity of the Elecsys HTLV-I/II was also 100.00%
(n = 500, 95% CI 99.26-100.00) since all specimens showed nonreactive results (S/CO < 1). The distribution pattern of S/CO values of 500 potential blood donors with the two assays is shown in Figure 2 .
ARCHITECT rHTLV-I/II demonstrated a narrower distribution pattern of S/CO values than that of Elecsys HTLV-I/II (P<0.001).
The total agreement between Elecsys HTLV-I/II and ARCHITECT rHTLV-I/II was 100%.
| D ISCUSS I ON
This study intended to evaluate the clinical sensitivity and specificity 
